Effects of central administration of insulin or l-NMMA on rat skeletal muscle microvascular perfusion

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2010-10, Vol.12 (10), p.900-908
• Main Authors: Bradley, E. A., Willson, K. J., Choi-Lundberg, D., Clark, M. G., Rattigan, S.
• Format: Article
• Language: English
• Subjects: Animals; Blood flow; Blood Glucose - metabolism; Blood pressure; Cerebrospinal fluid; Deoxyglucose; Glucose; Glucose metabolism; Heart rate; Hemodynamics; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - pharmacology; Injections, Intraventricular; Insulin - administration & dosage; Insulin - pharmacology; Insulin resistance; intracerebroventricular; Male; Microvasculature; muscle glucose uptake; muscle insulin action; Muscle, Skeletal - blood supply; Muscle, Skeletal - drug effects; Musculoskeletal system; Nitric oxide; Nitric-oxide synthase; omega-N-Methylarginine - administration & dosage; omega-N-Methylarginine - pharmacology; Perfusion; Rats; Rats, Wistar; Skeletal muscle
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/j.1463-1326.2010.01253.x

Aim: Intracerebroventricular (ICV) administration of a nitric oxide synthase (NOS) inhibitor to rats has been reported to raise blood pressure (BP) and cause insulin resistance, suggestive of a central effect of insulin that is NO dependent. Herein we test whether ICV insulin has peripheral haemodynamic and metabolic effects and whether peripheral effects of systemic insulin are affected by the ICV administration of the NOS inhibitor NG‐methyl‐l‐arginine (l‐NMMA). Methods: Anaesthetized rats were fitted with an ICV cannula for insulin, artificial cerebrospinal fluid (aCSF) or l‐NMMA infusion. Rats receiving ICV l‐NMMA (500 µg) underwent systemic insulin clamp (10 mU/min/kg) or saline treatment for 70 min and were compared with animals receiving an equal amount of l‐NMMA infused systemically. Results: ICV aCSF or insulin (135 mU/min/kg brain) for 70 min or systemic l‐NMMA (500 µg) had no effect on BP, heart rate (HR), femoral blood flow (FBF), glucose infusion rate, muscle 2‐deoxyglucose uptake, microvascular perfusion or plasma insulin. However, ICV l‐NMMA reduced systemic insulin‐mediated increases in FBF (2.05 ± 0.08 to 1.55 ± 0.15 ml/min), 2‐deoxyglucose uptake (17.7 ± 0.15 to 10.0 ± 0.03 µg/g/min) and microvascular perfusion (10.5 ± 0.5 to 6.6 ± 1.1 mol/min) (each mean ± SE, p < 0.05); plasma insulin, HR and BP were unaffected. Conclusions: Central insulin administration had no effect on skeletal muscle haemodynamics or glucose metabolism. However, systemic insulin‐mediated increases in limb blood flow, muscle microvascular perfusion and glucose uptake may be regulated by a central pathway that is NO dependent.